Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Cancer Immunol Res. 2021 Oct;9(10):1125-1140. doi: 10.1158/2326-6066.CIR-21-0137. Epub 2021 Aug 19.
Immunotherapy success in colorectal cancer is mainly limited to patients whose tumors exhibit high microsatellite instability (MSI). However, there is variability in treatment outcomes within this group, which is in part driven by the frequency and characteristics of tumor-infiltrating immune cells. Indeed, the presence of specific infiltrating immune-cell subsets has been shown to correlate with immunotherapy response and is in many cases prognostic of treatment outcome. Tumor-infiltrating lymphocytes (TIL) can undergo distinct differentiation programs, acquiring features of tissue-residency or exhaustion, a process during which T cells upregulate inhibitory receptors, such as PD-1, and lose functionality. Although residency and exhaustion programs of CD8 T cells are relatively well studied, these programs have only recently been appreciated in CD4 T cells and remain largely unknown in tumor-infiltrating natural killer (NK) cells. In this study, we used single-cell RNA sequencing (RNA-seq) data to identify signatures of residency and exhaustion in colorectal cancer-infiltrating lymphocytes, including CD8, CD4, and NK cells. We then tested these signatures in independent single-cell data from tumor and normal tissue-infiltrating immune cells. Furthermore, we used versions of these signatures designed for bulk RNA-seq data to explore tumor-intrinsic mutations associated with residency and exhaustion from TCGA data. Finally, using two independent transcriptomic datasets from patients with colon adenocarcinoma, we showed that combinations of these signatures, in particular combinations of NK-cell activity signatures, together with tumor-associated signatures, such as TGFβ signaling, were associated with distinct survival outcomes in patients with colon adenocarcinoma.
免疫疗法在结直肠癌中的成功主要局限于那些肿瘤表现出高度微卫星不稳定(MSI)的患者。然而,在这组患者中,治疗结果存在差异,部分原因是肿瘤浸润免疫细胞的频率和特征不同。事实上,特定浸润免疫细胞亚群的存在已被证明与免疫疗法反应相关,在许多情况下,也是治疗结果的预后因素。肿瘤浸润淋巴细胞(TIL)可以经历不同的分化程序,获得组织驻留或衰竭的特征,在此过程中,T 细胞上调抑制性受体,如 PD-1,并丧失功能。尽管 CD8 T 细胞的驻留和衰竭程序已经得到了相对较好的研究,但这些程序在 CD4 T 细胞中最近才被认识到,在肿瘤浸润自然杀伤(NK)细胞中仍然知之甚少。在这项研究中,我们使用单细胞 RNA 测序(RNA-seq)数据来鉴定结直肠癌浸润淋巴细胞(包括 CD8、CD4 和 NK 细胞)中驻留和衰竭的特征。然后,我们在来自肿瘤和正常组织浸润免疫细胞的独立单细胞数据中测试了这些特征。此外,我们使用了为批量 RNA-seq 数据设计的这些特征的版本,从 TCGA 数据中探索与驻留和衰竭相关的肿瘤内在突变。最后,使用来自结肠腺癌患者的两个独立转录组数据集,我们表明,这些特征的组合,特别是 NK 细胞活性特征的组合,与 TGFβ 信号等与肿瘤相关的特征一起,与结肠腺癌患者的不同生存结局相关。